NCT02527434 - Study of Tremelimumab in Patients With Advanced Solid Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 2, 2015

Primary Completion Date

February 17, 2018

Study Completion Date

March 28, 2023

Conditions

Urothelial Bladder CancerTriple-negative Breast CancerPancreatic Ductal Adenocarcinoma

Interventions

BIOLOGICAL

Tremelimumab monotherapy

IV infusion

BIOLOGICAL

MEDI4736 monotherapy

IV infusion

BIOLOGICAL

MEDI4736 + tremelimumab combination therapy

IV infusion

Trial Locations (14)

1090

Research Site, Brussels

2610

Research Site, Wilrijk

6000

Research Site, Charleroi

35015

Research Site, Daejeon

38120

Research Site, Memphis

77030

Research Site, Houston

94158

Research Site, San Francisco

9713 GZ

Research Site, Groningen

3584 CX

Research Site, Utrecht

80-214

Research Site, Gdansk

93-513

Research Site, Lodz

03080

Research Site, Seoul

03722

Research Site, Seoul

135-710

Research Site, Seoul